



























\* Fisher's exact test was used to assess the association of various factors with emergence of nevirapine resistance in HIV-infected infants. Relative risk for infant exposure to highly active antiretroviral therapy (HAART) was undefined, because none of the two infants exposed to HAART had resistance. Note that none of the infants received a non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing HAART regimen.

Abbreviations: CI: confidence intervals; ARV: antiretroviral; NVP: nevirapine; PMTCT: prevention of mother-to-child transmission; ZDV: zidovudine; HAART: highly active ARV treatment.

HIV genotyping results obtained for maternal plasma, breast milk and infant plasma samples from 8 mother-infant pairs where the mother started HAART by 6 months postpartum; all available samples were tested. Samples were collected at 6 weeks, and at 3 and 6 months postpartum. Mothers started HAART at 6 weeks (infants 5, 26, 27), 3 months (infants 33, 34), and 6 months (infants 2, 4, 9). HIV genotyping was not performed for maternal samples that had <400 copies/mL (c/mL) HIV RNA (VL < 400 c/mL).

<sup>a</sup> A nested polymerase chain reaction (PCR) procedure was required for amplification.

<sup>b</sup> HIV genotyping results for this infant did not include amino acids 8–32 in HIV reverse transcriptase. No major NNRTI or nucleoside/NRTI resistance mutations occur in that region of the reverse transcriptase protein.

